Joint Formulary & PAD

Formoterol (Easyhaler) - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :
Important

Not for initiation in new patients.

PAD Profile

ChemicalSubstance :
Formoterol (Easyhaler)
Indication :
Asthma
Group Name :
Keywords :
LABA, respiratory, asthmatics, Selective beta2-agonists, long-acting beta agonists
Brand Names Include :
Formoterol Easyhaler
Important Information :

LABA monotherapy no longer recommended for asthma or COPD.

Not to be initiated in new patients.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4

Other Indications

Below are listed other indications that Formoterol (Easyhaler) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Asthma.

Committee Recommendations (1)

Clenil Modulite® (beclometasone) MDI plus spacer (Volumatic, Able Spacer, Optichamber) or Qvar (beclometasone) MDI plus spacer (Aerochamber plus, Able Spacer, Optichamber) are the locally preferred ICS devices.

If an alternative device is necessary, consider:
Easyhaler® Beclometasone (DPI) - not licensed in under 18 years
Qvar Easi-Breathe® (breath activated) - not licensed in under 12 years
Easyhaler® Budesonide may be considered as an additional alternative in patients aged 12-17 if these other preferred, licensed devices are not suitable

Prescribe inhaler devices by BRAND to ensure consistency and avoid confusion.

See Asthma Guidelines below.